The cyclin-dependent kinase inhibitor, p27kip1, has no correlation with the malignant potential of GIST

Digestion

Volumn 75, Issue 1, 2007, Pages 4-9

  Shirin, Haim ^a,b   Kravtsov, Vladimir ^a   Shahmurov, Mark ^a   Sehayek Shabat, Vered ^a   Krinshpon, Ivgeni ^a   Alin, Avi ^a   Avinoach, Ilana ^a,b   Avni, Yona ^a,b  

^a WOLFSON MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

GIST; Ki 67; p27kip1

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CANCER RISK; CELL DEATH; CLINICAL FEATURE; EPITHELIOID CELL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; RISK ASSESSMENT; SPINDLE CELL; SURVIVAL RATE; SURVIVAL TIME; TISSUE SECTION;

ADULT; AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; MITOSIS; PROGNOSIS; PROTEIN KINASE INHIBITORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 34248203270     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000101457     Document Type: Article

References (41)

1. Sakurai S, Fukasawa T, Chong JM, Tanaka A, Fukuyama M: C-kit gene abnormalities in gastrointestinal stromal tumors (tumors of interstitial cells of Cajal). Jpn J Cancer Res 1999;90:1321-1328.
2. Mazur MT, Clark HB: Gastric stromal tumors: reappraisal of histogenesis. Am J Surg Pathol 1983;7:507-519.
3. Miettinen M, Majidi M, Lasota J: Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 2002;38(suppl 5):S39-S51.
4. Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CD, Fletcher JA: Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002;20:3898-3905.
5. Miettinen M, Sobin LH, Sarlomo-Rikala M: Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000;13:1134-1142.
6. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM: Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;156:1259-1269.
7. Shee-Chan L, Ming-Jer H, Chen-Yuan Z, Tzang-In W, Zen-Liang L, Ray-Kuan S: Clinical manifestations and prognostic factors in patients with gastrointestinal stromal tumors. World J Gastroenterol 2003;9:2809-2812.
8. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ: Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999;23:82-87.
9. Wong NA, Young R, Malcomson RD, Nayar AG, Jamieson LA, Save VE, Carey FA, Brewster DH, Han C, Al-Nafussi A: Prognostic indicators for gastrointestinal stromal tumors: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology 2003;43:118-126.
10. Yan H, Marchettini P, Acherman YI, Gething SA, Brun E, Sugarbaker PH: Prognostic assessment of gastrointestinal stromal tumor. Am J Clin Oncol 2003;26:221-228.
11. Koon N, Schneider-Stock R, Sarlomo-Rikala M, Lasota J, Smolkin M, Petroni G, Zaika A, Boltze C, Meyer F, Andersson L, Knuutila S, Miettinen M, El-Rifai W: Molecular targets for tumor progression in gastrointestinal stromal tumors. Gut 2004;53:235-240.
12. House MG, Guo M, Efron DT, Lillemoe KD, Cameron JL, Syphard JE, Hooker CM, Abraham SC, Montgomery EA, Herman JG, Brock MV: Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behavior. J Gastrointest Surg 2003;7: 1004-1014.
13. Montgomery E, Abraham SC, Fisher C, Deasel MR, Amr SS, Sheikh SS, House M, Lilliemoe K, Choti M, Brock M, Ephron DT, Zahuruk M, Chadburn A: CD44 loss in gastric stromal tumors as a prognostic marker. Am J Surg Pathol 2004;28:168-177.
14. Hunter T, Pines J: Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell 1994;79:573-582.
15. Grana X, Reddy PE: Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin dependent kinase inhibitors (CDIs). Oncogene 1995;11:211-219.
16. Tsihlias J, Kapusta L, Singerland J: The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med 1999;50:401-423.
17. kip1 is haplo-insufficient for tumor suppression. Nature 1998;396:177-180.
18. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, Akiyoshi T: p27 expression and gastric carcinoma. Nat Med 1997;3: 259.
19. Singh SP, Lipman J, Goldman H, Ellis FH Jr, Ainzenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M: Loss of altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 1998;58:1730-1735.
20. kip1 in multistage colorectal carcinogenesis. Cancer Res 1998; 58:114-122.
21. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW: Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathol 2002;33:459-465.
22. kip1 expression distinguishes papillary hyperplasia in Grave's disease from papillary thyroid carcinoma. Mod Pathol 2000;13:1014-1019.
23. Tavassoli FA: Immunocytochemical determination of ER and PR. In: Tavassoli FA (ed): Pathology of the Breast, ed 2. New York, Appleton & Lange, 1999, p 53.
24. Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, McCarty KS Jr: Immunohistochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res 1989;49: 1052-1056.
25. Weiss LM, Strickler JG, Medeiros LJ, Gerdes J, Stein H, Warnke RA: Proliferative rates of non-Hodgkin's lymphomas as assessed by Ki-67 antibody. Human Pathol 1987;18: 1155-1159.
26. Nakamura N, Yamamoto H, Yao T, Oda Y, Nishiyama K, Imamura M, Yamada T, Nawata H, Tsuneyoshi M: Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal tumor and the relevance of the risk grade. Human Pathol 2005; 36:828-837.
27. Chetty R: p27 protein and cancers of the gastrointestinal tract and liver: an overview. J Clin Gastroenterol 2003;37:23-27.
28. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-234.
29. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW: p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999;154:313-323.
30. Seidal T, Edvardsson H: Expression of c-kit (CD 117) and Ki-67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumors. Histopathology 1999;34:416-424.
31. Cunningham RE, Abbondanzo SL, Chu WS, Emory TS, Sobin LH, O'Leary TJ: Apoptosis, bcl-2 expression, and p53 expression in gastrointestinal stroma/smooth muscle tumors. Appl Immunohistochem Mol Morphol 2001; 9:19-23.
32. Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S: Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Human Pathol 2002;33:669-676.
33. Kim NG, Kim JJ, Ahn JY, Seong CM, Noh SH, Kim CB, Min JS, Kim H: Putative chromosomal deletions on 9P, 9Q, and 22Q occur preferentially in malignant gastrointestinal stromal tumors. Int J Cancer 2000;85:633-638.
34. Panizo-Santos A, Sola I, Vega F, de Alava E, Lozano MD, Pardo-Mindan J: Predicting metastatic risk of gastrointestinal stromal tumors: role of cell proliferation and cell cycle regulatory proteins. Int J Surg Pathol 2000;8:133-144.
35. Hillemanns M, Pasold S, Bottcher K, Hofler H: Prognostic factors of gastrointestinal stromal tumors of the stomach. Verh Dtsch Ges Pathol 1998:82:261-266.
36. Debiec-Rychter M, Lasota J, Sarlomo-Rikala M, Kordek R, Miettinen M: Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation. Cancer Genet Cytogenet 2001; 128:24-30.
37. Toquet C, Le Neel JC, Guillou L, Renaudin K, Hamy A, Heymann MF, Simon-Valla S, Le Borgne J, Maugard C, Iche M: Elevated (≥10%) MIB-1 proliferative index correlates with poor outcome in gastric stromal tumor patients. Dig Dis Sci 2002;47:2247-2253.
38. Pruneri G, Mazzarol G, Fabris S, Del Curto B, Bertolini F, Neri A, Viale G: Cyclin D3 immunoreactivity in gastrointestinal stromal tumors is independent of cyclin D3 gene amplification and is associated with nuclear p27 accumulation. Mod Pathol 2003;16:886-892.
39. Gelen TG, Elpek GO, Aksoy NH, Ogus M, Keles N: p27 labeling index and proliferating gastrointestinal stromal tumors: correlations with clinicopathologic factors and recurrence. Jap J Clin Oncol 2003;33:346-352.
40. Kip1 in human breast cancers. Clin Cancer Res 1997;3:1879-1887.
41. Sanchez-Beato M, Camacho FI, Martinez-Montero JC, Saez AI, Villuendas R, Sanchez-Verde L, Garcia JF, Piris MA: Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression: p27/KIP1-cyclin D3 colocalization in tumor cells. Blood 1999; 94:765-772.